172 Preclinical profile of ABP309, a potent 2nd generation VEGF receptor tyrosine kinase inhibitor belonging to the class of aminonicotinamides

2004 ◽  
Vol 2 (8) ◽  
pp. 54-55
Author(s):  
J. Brueggen ◽  
G. Bold ◽  
R. Cozens ◽  
P.W. Manley ◽  
J. Mestan ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor ◽  
2Nd Generation

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S182
Author(s):  
Catherine Wheeler ◽  
Hironobu Minami ◽  
Hiromichi Ebi ◽  
Makoto Tahara ◽  
Yasutsuna Sasaki ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Receptor Tyrosine Kinase ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor

scholarly journals The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

2017 ◽  
Vol 116 (11) ◽  
pp. 1402-1407 ◽  
Author(s):  
Rachna T Shroff ◽  
Mark Yarchoan ◽  
Ashley O'Connor ◽  
Denise Gallagher ◽  
Marianna L Zahurak ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Mek Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document